{
  "docId": "019de072-ef20-75e9-922b-a59946a49f08",
  "docSlug": "b6265fe9aad535c251b3bd786fc797fa",
  "documentTitle": "BioAtla | Investor Conference Presentation Deck | 15 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 15,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 8,
  "notes": "The slide highlights the first-in-class potential of the CAB-ROR2-ADC therapy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-ef20-75e9-922b-a59946a49f08/12",
  "deckHref": "/decks/019de072-ef20-75e9-922b-a59946a49f08",
  "deckJsonHref": "/decks/019de072-ef20-75e9-922b-a59946a49f08.json",
  "deckAnchorHref": "/decks/019de072-ef20-75e9-922b-a59946a49f08#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.01,
        "y": 0.315
      },
      "kind": "callout",
      "text": "No ROR2 ADC or small molecules in the clinic to date, suggesting CAB-ROR2-ADC is potentially a first-in-class therapy across multiple tumor types",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "45276a6a-5737-4546-8746-5bef6dc86dde",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.6,
        "x": 0.31,
        "y": 0.185
      },
      "kind": "list",
      "text": "Phase 1 study: NSCLC (PR n=2/3), Melanoma (CR n=1/1), SCCHN (PR n=1/1), Promising safety profile",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "75ffaa79-31ae-42a3-9ddf-16b325c66643",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.6,
        "x": 0.31,
        "y": 0.53
      },
      "kind": "list",
      "text": "Phase 2 studies: NSCLC (n=40), Melanoma (n=40, CR n=1/1), SCCHN (n=40)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "825a465c-c4a3-4070-8462-132be72c76b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.7,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Encouraging Phase 1 results with BA3021 support advancing into Phase 2 in multiple indications",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca84a60f-54ec-4ff5-9eee-980144c0152e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}